Skip to main content
MyPeptideMatch logoMyPeptideMatch
Reviewed by MyPeptideMatch Editorial TeamLast reviewed February 2026Updated February 2026

5-Amino-1MQ Dosing Protocol: 50 mg Vial — NNMT Inhibition & Metabolic Guide

5-Amino-1-methylquinolinium (5-Amino-1MQ) dosing protocol — NNMT inhibitor for fat loss, metabolic rate enhancement, and NAD+ preservation.

Go to peptide profileCalculate your dose

Quickstart highlights

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a membrane-permeable small molecule NNMT inhibitor.

  • Concentration: 5 mg/mL (50 mg vial + 10 mL bacteriostatic water).
  • Oral administration strongly preferred — 50 mg injectable volume (10 mL) is impractical for SC use.
  • Neelakantan et al. 2019: 5-Amino-1MQ reduced adipocyte size 30%, increased metabolic rate in HFD mice.
  • NNMT inhibition preserves both NAD+ and SAM for energy metabolism and epigenetic maintenance.
  • Start at 50 mg/day; advance to 100–150 mg/day if tolerated without side effects.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4——Once daily (oral or SC)50 mg starting dose; assess metabolic response (thermogenesis, energy) before advancing
5-12——Once daily (oral or SC)100 mg maintenance dose; one 50 mg vial provides 1 dose at this level — oral capsule form typically more practical for 100+ mg

Reconstitution steps

  1. Draw 10 mL bacteriostatic water (four 2.5 mL draws); inject slowly down the vial wall.
  2. Swirl gently until dissolved; do not shake.
  3. Final concentration: 5 mg/mL. At 5 mg/mL: 50 mg = 10 mL; 100 mg requires two vials.
  4. Label with date; refrigerate at 2–8 °C. Use within 28 days. Oral use: dissolve in water or swallow directly.

Supplies needed

12-week plan

  • 14 vials
  • 84 syringes
  • 140 mL bac water
  • 84 alcohol swabs
Need clinics? See vetted providers →

Protocol overview & cycle notes

Inhibit NNMT (nicotinamide N-methyltransferase) to preserve NAD+ and SAM levels in adipose tissue, increasing metabolic rate, reducing fat cell lipogenesis, and enhancing systemic energy expenditure.

Cycle length: 12 weeks on.

Off-cycle: 8 weeks off; reassess body composition and metabolic markers before resuming.

Storage & handling

Lyophilized: store below 25 °C. Reconstituted: refrigerate 2–8 °C, use within 28 days. Note: at 50 mg/day SC, the injection volume is 10 mL — impractical for subcutaneous injection; oral administration is strongly preferred for this compound. SC injection is limited to 2–5 mL per site maximum.

Injection & tracking tips

  • Oral administration is strongly preferred for 5-Amino-1MQ — the large dose (50–150 mg) requires excessive injection volume (10–30 mL) that is impractical for subcutaneous use.
  • If using SC: limit to 25 mg (5 mL at 5 mg/mL) per injection site; inject across multiple abdomen sites simultaneously.
  • Take on an empty stomach or with a low-fat meal for best absorption; fatty meals may slow NNMT inhibitor uptake.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure body composition (InBody scan) at baseline and every 4 weeks.
  • Track resting heart rate, thermogenesis sensation, and energy levels daily for metabolic rate changes.
  • Monitor SAM (S-adenosylmethionine) and methionine levels if available — NNMT inhibition preserves SAM for methylation reactions.
Log your cycle in the calculator →

How this works & references

5-Amino-1MQ (5-amino-1-methylquinolinium iodide) is a membrane-permeable small molecule NNMT inhibitor. NNMT is an enzyme highly expressed in white adipose tissue that converts nicotinamide to 1-methylnicotinamide (MNA), consuming SAM (S-adenosylmethionine) in the process. Overactive NNMT in obesity: (1) depletes NAD+ precursors; (2) depletes SAM, reducing histone methylation capacity and epigenetic maintenance; (3) promotes adipogenesis. Kannt et al. (2015, Sci Rep) showed NNMT-knockout mice are protected from diet-induced obesity. Neelakantan et al. (2019, Nat Commun) demonstrated 5-Amino-1MQ reduced adipocyte size by 30%, increased metabolic rate, and prevented weight gain in high-fat-diet mice without food restriction.

Sources

  • Source: Neelakantan H et al. — Small molecule NNMT inhibitor activates thermogenic adipose tissue. Nat Commun. 2019;10:5567
  • Source: Kannt A et al. — Inhibition of nicotinamide N-methyltransferase reduces obesity. Sci Rep. 2015;5:11270

Frequently asked questions

Is 5-Amino-1MQ best taken orally or by injection?
Oral administration is strongly preferred for 5-Amino-1MQ due to dose size: 50–150 mg requires 10–30 mL injection volume at 5 mg/mL — beyond the 2–5 mL per site limit for subcutaneous injection. The compound is orally bioavailable based on mouse pharmacokinetic data. Oral capsule formulation is the standard human delivery method.
How quickly does 5-Amino-1MQ produce fat loss effects?
In Neelakantan et al. (2019), measurable differences in adipocyte size and adiposity appeared within 6 weeks in mice. Human users typically report increased thermogenesis (warmth, elevated resting heart rate) within 1–2 weeks and measurable body composition changes at 6–12 weeks. Fat loss is approximately 1–2% of body fat over 12 weeks in responding individuals.
Does 5-Amino-1MQ cause muscle loss?
No — unlike calorie restriction or semaglutide-class drugs, 5-Amino-1MQ's mechanism targets adipose NNMT, not muscle NNMT. Adipose-specific SAM preservation and thermogenesis increase fat oxidation while sparing muscle protein. Some protocols combine 5-Amino-1MQ with MK-677 or GHRP-6 to maintain anabolic stimulus during caloric deficits.
Is 5-Amino-1MQ FDA-approved?
No — 5-Amino-1MQ is a research compound with no FDA approval or IND status as of 2026. It is available through compounding pharmacies as an experimental compound. No human clinical trials have been registered or completed.
Can 5-Amino-1MQ be combined with NAD+ precursors (NMN/NR)?
Yes — this is a pharmacologically rational combination: NMN/NR supplements increase NAD+ by providing the nicotinamide riboside substrate; 5-Amino-1MQ inhibits NNMT, reducing wasteful degradation of nicotinamide. Together, they optimize both the supply and preservation of the NAD+ pool.

Related protocols

Vilon Dosing Protocol: 20 mg Vial — Dipeptide Immune & Longevity Bioregulator Guide

Vilon (Lys-Glu dipeptide) Russian immune and longevity bioregulator dosing guide — the simplest Khavinson bioregulator for systemic immune normalization and longevity support.

View protocol

Vesugen Dosing Protocol: 20 mg Vial — Vascular Bioregulator & Cardiovascular Guide

Vesugen (Lys-Glu-Asp tetrapeptide) Russian vascular bioregulator dosing guide — endothelial cell gene normalization for arterial health, blood pressure regulation, and cardiovascular aging.

View protocol

Testagen Dosing Protocol: 20 mg Vial — Testicular Bioregulator & Testosterone Support Guide

Testagen (Lys-Glu-Asp-Gly tetrapeptide) Russian testicular bioregulator dosing guide — Leydig cell gene normalization for testosterone production optimization and male reproductive aging support.

View protocol

Prostamax Dosing Protocol: 20 mg Vial — Prostate Bioregulator Guide

Prostamax (Lys-Asp-Glu-Leu tetrapeptide) Russian prostate bioregulator dosing guide — prostatic epithelial gene normalization for BPH, prostate aging, and urinary symptom support.

View protocol

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Need help?

Browse vetted clinicsView full peptide profile →